In short
Clinical trials are investigating AZD0292 in people with bronchiectasis and chronic pseudomonas aeruginosa colonization. These studies aim to assess how well AZD0292 works, how safe it is, and how it moves through the body over time. The main focus is on adults with non-cystic fibrosis bronchiectasis and long-term PsA colonization.
Key points
- AZD0292 is being studied in clinical trials for people with bronchiectasis and chronic pseudomonas aeruginosa colonization. The available trial is a Phase 2 interventional study with 435 participants. It compares AZD0292 with placebo and looks at safety, how the drug moves through the body, and whether it lowers the rate of moderate-to-severe lung flare-ups. The main outcome is the annualized rate of exacerbations over a variable follow-up time. The study is authorised and focuses on adults with non-cystic fibrosis bronchiectasis.
Trial overview
This trial is studying AZD0292 in people with bronchiectasis and chronic pseudomonas aeruginosa colonization.
The trial title says it is designed to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time.
The brief summary says the study compares IV AZD0292 with placebo to evaluate the effect on the rate of moderate-to-severe pulmonary exacerbations in participants with non-cystic fibrosis bronchiectasis and chronic PsA colonization.
Who is being studied
The target population is people with non-cystic fibrosis bronchiectasis, also called NCFBE, and chronic PsA colonization.
Bronchiectasis is a long-term lung condition in which the airways are damaged and widened, which can lead to repeated infections and flare-ups.
Chronic colonization means the bacteria stay present over time, rather than being a short-term infection.
Trial design and treatment groups
This is an interventional study, which means researchers give a treatment and then measure what happens.
The trial includes two study groups: AZD0292 given as a solution for infusion and placebo for AZD0292.
A placebo is an inactive treatment used for comparison so researchers can better see whether the study drug makes a difference.
The trial is in Phase 2, which is a stage that usually looks more closely at whether a treatment may work while continuing to monitor safety.
The enrollment is 435 participants.
What the trial is measuring
The main endpoint is the annualized rate of exacerbations over a variable follow-up time.
An exacerbation is a worsening of symptoms, and in this trial it refers to moderate-to-severe pulmonary, or lung, flare-ups.
“Annualized rate” means the number of events is measured as a yearly rate, so researchers can compare how often flare-ups happen in the study groups.
The title also says the study will look at how AZD0292 moves throughout the body over time, which is often called pharmacokinetics, but the trial data do not give further details beyond that goal.
Trial status and phase
The trial status is Authorised, which means it has been approved to proceed according to the trial record.
The study phase is Phase 2, so the main focus is on early evidence of benefit and continued safety checking in a defined patient group.
Based on the trial record, this is currently the only listed study of AZD0292 in the provided data.